FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380884022> ?p ?o ?g. }

• W4380884022 endingPage "391.e21" @default.
• W4380884022 startingPage "391.e13" @default.
• W4380884022 abstract "While surgical management of renal cell carcinoma (RCC) is curative for many patients, others may relapse and could benefit from adjuvant treatments. Immune checkpoint inhibitors (ICI) have been proposed as a potential adjuvant therapy for improving survival in these patients, but the benefit/risk ratio of ICI in the perioperative setting remains unclear. A systematic review and a meta-analysis of phase III trials of perioperative ICI (anti PD1/PD-L1 alone or in combination with anti-CTLA4 agents) in RCC was conducted. The analysis included results from 4 phase III trials, comprising 3,407 patients. ICI did not show a significant increase in disease-free survival (Hazard Ratio [HR] 0.85; 95% confidence interval [CI] 0.69–1.04; p: 0.11) or overall survival [OS] (HR 0.73; 95% CI 0.40–1.34; p: 0.31). High-grade adverse events were more frequent in the immunotherapy arm (OR 2.65; 95% CI 1.53-4.59; p: <0.001), and high-grade treatment-related adverse events were 8 times more frequent in the experimental arm (OR: 8.07; 95% CI: 3.14–20.75; p: <0.001). Subgroup analyses showed statistically significant differences favoring the experimental arm in females (HR: 0.71; 95 CI 0.55–0.92; p: 0.009), in sarcomatoid differentiation (HR: 0.60 95% CI 0.41–0.89; p: 0.01), and PD-L1 positive tumors (HR HR: 0.74; 95% CI 0.61–0.90; p: 0.003). No significant effect was found in patients according to age, type of nephrectomy (radical vs. partial), and stage (M1 without evidence of disease vs. M0 patients). Our comprehensive meta-analysis generally suggests that immunotherapy does not confer a survival advantage in the perioperative setting for RCC, with the exception of one positive study. While the overall results are not statistically significant, individual patient factors and other variables may play a role in determining who benefits from immunotherapy. Therefore, despite the mixed findings, immunotherapy may still be a viable treatment option for certain patients, and further studies are needed to determine which patient subgroups would be most likely to benefit." @default.
• W4380884022 created "2023-06-17" @default.
• W4380884022 creator A5016133659 @default.
• W4380884022 creator A5016856917 @default.
• W4380884022 creator A5024147987 @default.
• W4380884022 creator A5054850662 @default.
• W4380884022 creator A5058652974 @default.
• W4380884022 creator A5058718946 @default.
• W4380884022 creator A5065945024 @default.
• W4380884022 creator A5074162105 @default.
• W4380884022 date "2023-09-01" @default.
• W4380884022 modified "2023-10-03" @default.
• W4380884022 title "Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out" @default.
• W4380884022 cites W1821331647 @default.
• W4380884022 cites W2077421021 @default.
• W4380884022 cites W2083887116 @default.
• W4380884022 cites W2137970869 @default.
• W4380884022 cites W2293077587 @default.
• W4380884022 cites W2530419161 @default.
• W4380884022 cites W2541143748 @default.
• W4380884022 cites W2756219586 @default.
• W4380884022 cites W2776932204 @default.
• W4380884022 cites W2786438413 @default.
• W4380884022 cites W2792937256 @default.
• W4380884022 cites W2896175597 @default.
• W4380884022 cites W2946850088 @default.
• W4380884022 cites W2952305731 @default.
• W4380884022 cites W2970684805 @default.
• W4380884022 cites W3010304885 @default.
• W4380884022 cites W3014505556 @default.
• W4380884022 cites W3015470279 @default.
• W4380884022 cites W3019350884 @default.
• W4380884022 cites W3024966661 @default.
• W4380884022 cites W3042347895 @default.
• W4380884022 cites W3042364418 @default.
• W4380884022 cites W3047001933 @default.
• W4380884022 cites W3081958456 @default.
• W4380884022 cites W3092785514 @default.
• W4380884022 cites W3122642980 @default.
• W4380884022 cites W4214638981 @default.
• W4380884022 cites W4293083605 @default.
• W4380884022 cites W4293708418 @default.
• W4380884022 cites W4295752424 @default.
• W4380884022 cites W4295837466 @default.
• W4380884022 cites W4319660667 @default.
• W4380884022 cites W4322718735 @default.
• W4380884022 doi "https://doi.org/10.1016/j.urolonc.2023.05.002" @default.
• W4380884022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37331822" @default.
• W4380884022 hasPublicationYear "2023" @default.
• W4380884022 type Work @default.
• W4380884022 citedByCount "0" @default.
• W4380884022 crossrefType "journal-article" @default.
• W4380884022 hasAuthorship W4380884022A5016133659 @default.
• W4380884022 hasAuthorship W4380884022A5016856917 @default.
• W4380884022 hasAuthorship W4380884022A5024147987 @default.
• W4380884022 hasAuthorship W4380884022A5054850662 @default.
• W4380884022 hasAuthorship W4380884022A5058652974 @default.
• W4380884022 hasAuthorship W4380884022A5058718946 @default.
• W4380884022 hasAuthorship W4380884022A5065945024 @default.
• W4380884022 hasAuthorship W4380884022A5074162105 @default.
• W4380884022 hasConcept C121608353 @default.
• W4380884022 hasConcept C126322002 @default.
• W4380884022 hasConcept C141071460 @default.
• W4380884022 hasConcept C143998085 @default.
• W4380884022 hasConcept C187960798 @default.
• W4380884022 hasConcept C197934379 @default.
• W4380884022 hasConcept C207103383 @default.
• W4380884022 hasConcept C2777472916 @default.
• W4380884022 hasConcept C2777701055 @default.
• W4380884022 hasConcept C2777863537 @default.
• W4380884022 hasConcept C2777982462 @default.
• W4380884022 hasConcept C31174226 @default.
• W4380884022 hasConcept C44249647 @default.
• W4380884022 hasConcept C71924100 @default.
• W4380884022 hasConcept C90924648 @default.
• W4380884022 hasConcept C95190672 @default.
• W4380884022 hasConceptScore W4380884022C121608353 @default.
• W4380884022 hasConceptScore W4380884022C126322002 @default.
• W4380884022 hasConceptScore W4380884022C141071460 @default.
• W4380884022 hasConceptScore W4380884022C143998085 @default.
• W4380884022 hasConceptScore W4380884022C187960798 @default.
• W4380884022 hasConceptScore W4380884022C197934379 @default.
• W4380884022 hasConceptScore W4380884022C207103383 @default.
• W4380884022 hasConceptScore W4380884022C2777472916 @default.
• W4380884022 hasConceptScore W4380884022C2777701055 @default.
• W4380884022 hasConceptScore W4380884022C2777863537 @default.
• W4380884022 hasConceptScore W4380884022C2777982462 @default.
• W4380884022 hasConceptScore W4380884022C31174226 @default.
• W4380884022 hasConceptScore W4380884022C44249647 @default.
• W4380884022 hasConceptScore W4380884022C71924100 @default.
• W4380884022 hasConceptScore W4380884022C90924648 @default.
• W4380884022 hasConceptScore W4380884022C95190672 @default.
• W4380884022 hasIssue "9" @default.
• W4380884022 hasLocation W43808840221 @default.
• W4380884022 hasLocation W43808840222 @default.
• W4380884022 hasOpenAccess W4380884022 @default.
• W4380884022 hasPrimaryLocation W43808840221 @default.
• W4380884022 hasRelatedWork W1900595920 @default.

• next